The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sexual Dysfunction Drugs Market Research Report 2025
Synopsis
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market.
The global Sexual Dysfunction Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Sexual Dysfunction Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sexual Dysfunction Drugs.
Report Scope
The Sexual Dysfunction Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sexual Dysfunction Drugs market comprehensively. Regional market sizes, concerning products by Type, by User, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sexual Dysfunction Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by User, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
Segment by Type
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sexual Dysfunction Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sexual Dysfunction Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market.
The global Sexual Dysfunction Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Sexual Dysfunction Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sexual Dysfunction Drugs.
Report Scope
The Sexual Dysfunction Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sexual Dysfunction Drugs market comprehensively. Regional market sizes, concerning products by Type, by User, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sexual Dysfunction Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by User, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
Segment by Type
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sexual Dysfunction Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sexual Dysfunction Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Sexual Dysfunction Drugs Market Overview
1.1 Product Overview and Scope of Sexual Dysfunction Drugs
1.2 Sexual Dysfunction Drugs Segment by Type
1.2.1 Global Sexual Dysfunction Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Oral Therapy
1.2.3 Intracavernosal Therapy
1.2.4 Hormonal Therapy
1.2.5 Transurethral Therapy
1.3 Sexual Dysfunction Drugs Segment by User
1.3.1 Global Sexual Dysfunction Drugs Market Value by User: (2024-2030)
1.3.2 Male
1.3.3 Female
1.4 Global Sexual Dysfunction Drugs Market Size Estimates and Forecasts
1.4.1 Global Sexual Dysfunction Drugs Revenue 2019-2030
1.4.2 Global Sexual Dysfunction Drugs Sales 2019-2030
1.4.3 Global Sexual Dysfunction Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Sexual Dysfunction Drugs Market Competition by Manufacturers
2.1 Global Sexual Dysfunction Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Sexual Dysfunction Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Sexual Dysfunction Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Sexual Dysfunction Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Sexual Dysfunction Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sexual Dysfunction Drugs, Product Type & Application
2.7 Sexual Dysfunction Drugs Market Competitive Situation and Trends
2.7.1 Sexual Dysfunction Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Sexual Dysfunction Drugs Players Market Share by Revenue
2.7.3 Global Sexual Dysfunction Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Sexual Dysfunction Drugs Retrospective Market Scenario by Region
3.1 Global Sexual Dysfunction Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Sexual Dysfunction Drugs Global Sexual Dysfunction Drugs Sales by Region: 2019-2030
3.2.1 Global Sexual Dysfunction Drugs Sales by Region: 2019-2024
3.2.2 Global Sexual Dysfunction Drugs Sales by Region: 2025-2030
3.3 Global Sexual Dysfunction Drugs Global Sexual Dysfunction Drugs Revenue by Region: 2019-2030
3.3.1 Global Sexual Dysfunction Drugs Revenue by Region: 2019-2024
3.3.2 Global Sexual Dysfunction Drugs Revenue by Region: 2025-2030
3.4 North America Sexual Dysfunction Drugs Market Facts & Figures by Country
3.4.1 North America Sexual Dysfunction Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Sexual Dysfunction Drugs Sales by Country (2019-2030)
3.4.3 North America Sexual Dysfunction Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Sexual Dysfunction Drugs Market Facts & Figures by Country
3.5.1 Europe Sexual Dysfunction Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Sexual Dysfunction Drugs Sales by Country (2019-2030)
3.5.3 Europe Sexual Dysfunction Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sexual Dysfunction Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Sexual Dysfunction Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Sexual Dysfunction Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Sexual Dysfunction Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Sexual Dysfunction Drugs Market Facts & Figures by Country
3.7.1 Latin America Sexual Dysfunction Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Sexual Dysfunction Drugs Sales by Country (2019-2030)
3.7.3 Latin America Sexual Dysfunction Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Sexual Dysfunction Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Sexual Dysfunction Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Sexual Dysfunction Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Sexual Dysfunction Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Sexual Dysfunction Drugs Sales by Type (2019-2030)
4.1.1 Global Sexual Dysfunction Drugs Sales by Type (2019-2024)
4.1.2 Global Sexual Dysfunction Drugs Sales by Type (2025-2030)
4.1.3 Global Sexual Dysfunction Drugs Sales Market Share by Type (2019-2030)
4.2 Global Sexual Dysfunction Drugs Revenue by Type (2019-2030)
4.2.1 Global Sexual Dysfunction Drugs Revenue by Type (2019-2024)
4.2.2 Global Sexual Dysfunction Drugs Revenue by Type (2025-2030)
4.2.3 Global Sexual Dysfunction Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Sexual Dysfunction Drugs Price by Type (2019-2030)
5 Segment by User
5.1 Global Sexual Dysfunction Drugs Sales by User (2019-2030)
5.1.1 Global Sexual Dysfunction Drugs Sales by User (2019-2024)
5.1.2 Global Sexual Dysfunction Drugs Sales by User (2025-2030)
5.1.3 Global Sexual Dysfunction Drugs Sales Market Share by User (2019-2030)
5.2 Global Sexual Dysfunction Drugs Revenue by User (2019-2030)
5.2.1 Global Sexual Dysfunction Drugs Revenue by User (2019-2024)
5.2.2 Global Sexual Dysfunction Drugs Revenue by User (2025-2030)
5.2.3 Global Sexual Dysfunction Drugs Revenue Market Share by User (2019-2030)
5.3 Global Sexual Dysfunction Drugs Price by User (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Sexual Dysfunction Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Sexual Dysfunction Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Sexual Dysfunction Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Eli Lilly
6.4.1 Eli Lilly Corporation Information
6.4.2 Eli Lilly Description and Business Overview
6.4.3 Eli Lilly Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly Sexual Dysfunction Drugs Product Portfolio
6.4.5 Eli Lilly Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Corporation Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 AbbVie Sexual Dysfunction Drugs Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bayer Sexual Dysfunction Drugs Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 Teva Pharmaceutical Industries
6.6.1 Teva Pharmaceutical Industries Corporation Information
6.6.2 Teva Pharmaceutical Industries Description and Business Overview
6.6.3 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Product Portfolio
6.7.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.8 Takeda
6.8.1 Takeda Corporation Information
6.8.2 Takeda Description and Business Overview
6.8.3 Takeda Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Sexual Dysfunction Drugs Product Portfolio
6.8.5 Takeda Recent Developments/Updates
6.9 Apricus Biosciences
6.9.1 Apricus Biosciences Corporation Information
6.9.2 Apricus Biosciences Description and Business Overview
6.9.3 Apricus Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Apricus Biosciences Sexual Dysfunction Drugs Product Portfolio
6.9.5 Apricus Biosciences Recent Developments/Updates
6.10 Emotional Brain
6.10.1 Emotional Brain Corporation Information
6.10.2 Emotional Brain Description and Business Overview
6.10.3 Emotional Brain Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Emotional Brain Sexual Dysfunction Drugs Product Portfolio
6.10.5 Emotional Brain Recent Developments/Updates
6.11 Ivix LLX
6.11.1 Ivix LLX Corporation Information
6.11.2 Ivix LLX Sexual Dysfunction Drugs Description and Business Overview
6.11.3 Ivix LLX Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Ivix LLX Sexual Dysfunction Drugs Product Portfolio
6.11.5 Ivix LLX Recent Developments/Updates
6.12 Leadiant Biosciences
6.12.1 Leadiant Biosciences Corporation Information
6.12.2 Leadiant Biosciences Sexual Dysfunction Drugs Description and Business Overview
6.12.3 Leadiant Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Leadiant Biosciences Sexual Dysfunction Drugs Product Portfolio
6.12.5 Leadiant Biosciences Recent Developments/Updates
6.13 NexMed
6.13.1 NexMed Corporation Information
6.13.2 NexMed Sexual Dysfunction Drugs Description and Business Overview
6.13.3 NexMed Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 NexMed Sexual Dysfunction Drugs Product Portfolio
6.13.5 NexMed Recent Developments/Updates
6.14 S1 Biopharma
6.14.1 S1 Biopharma Corporation Information
6.14.2 S1 Biopharma Sexual Dysfunction Drugs Description and Business Overview
6.14.3 S1 Biopharma Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 S1 Biopharma Sexual Dysfunction Drugs Product Portfolio
6.14.5 S1 Biopharma Recent Developments/Updates
6.15 Vietstar Biomedical Research
6.15.1 Vietstar Biomedical Research Corporation Information
6.15.2 Vietstar Biomedical Research Sexual Dysfunction Drugs Description and Business Overview
6.15.3 Vietstar Biomedical Research Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Vietstar Biomedical Research Sexual Dysfunction Drugs Product Portfolio
6.15.5 Vietstar Biomedical Research Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sexual Dysfunction Drugs Industry Chain Analysis
7.2 Sexual Dysfunction Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sexual Dysfunction Drugs Production Mode & Process
7.4 Sexual Dysfunction Drugs Sales and Marketing
7.4.1 Sexual Dysfunction Drugs Sales Channels
7.4.2 Sexual Dysfunction Drugs Distributors
7.5 Sexual Dysfunction Drugs Customers
8 Sexual Dysfunction Drugs Market Dynamics
8.1 Sexual Dysfunction Drugs Industry Trends
8.2 Sexual Dysfunction Drugs Market Drivers
8.3 Sexual Dysfunction Drugs Market Challenges
8.4 Sexual Dysfunction Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
